Highland Instruments

What an Investor Needs First

Highland Instruments is a clinical-stage medical device company developing a novel, noninvasive neuromodulation platform for chronic pain and neurodegenerative diseases. Founded in 2017 by scientists from Harvard Medical School and MIT, the company's core technology, ESStim, combines electromagnetic and ultrasonic fields to stimulate neural tissue. Current operations are funded by non-dilutive government grants, including an SBIR grant totaling $850,000 and undisclosed awards from the NIH [CBInsights] [PRNewswire, Aug 2022].

Data Accuracy: YELLOW -- Core company facts and grant funding are confirmed; team size and revenue figures are from single, unverified sources.

Taxonomy Snapshot

Axis	Value
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Academic Spinout

Inside the Company

Highland Instruments was founded in 2017, emerging from a scientific background at Harvard Medical School and MIT [Crunchbase] [ZoomInfo]. The company is headquartered in Braintree, Massachusetts, and has operated as a research-focused entity, primarily supported by non-dilutive government grants [CBInsights].

The company's development timeline is anchored by a series of clinical trials for its core ESStim technology. An early milestone was IRB approval for a clinical evaluation in Parkinson's Disease patients in 2012 [Business Wire, Oct 2012]. Subsequent years saw the completion of multiple randomized, double-blind, placebo-controlled trials for conditions including chronic osteoarthritis knee pain and carpal tunnel syndrome, with results presented in partnership with Spaulding Rehabilitation Hospital at Harvard Medical School [PRNewswire] [BioSpace]. In 2022, the company was awarded additional NIH funding to support studies for opioid use disorder [PRNewswire, Aug 2022].

Data Accuracy: YELLOW -- Core founding details and clinical trial announcements are confirmed by multiple public sources; employee and revenue figures are from single, unverified commercial databases.

Under the Hood

Highland Instruments' commercial proposition rests on its proprietary ESStim neuromodulation platform. The core technology, described as "electrosonic stimulation," integrates Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) into a single device [Highland Instruments website]. The company's thesis is that the combined electromagnetic and ultrasonic fields produce a synergistic effect, enhancing stimulation in neural tissue [ZoomInfo].

The system is supported by AI, medical imaging, wearable sensors, and movement kinematics analysis [Highland Instruments website]. The most substantive public evidence for the product's development are the results from multiple clinical trials. The company and its research partners have reported positive outcomes from randomized, double-blind, placebo-controlled studies for conditions including chronic osteoarthritis knee pain, Parkinson's disease, and carpal tunnel syndrome [PRNewswire] [Physical Therapy Products] [BioSpace].

Data Accuracy: YELLOW -- Core technology claims are from the company website and corroborated by third-party summaries. Clinical trial outcomes are reported in press releases from the company and its hospital partners.

Market Research

The market for noninvasive neuromodulation is expanding, driven by a persistent unmet need for alternatives to pharmaceuticals in chronic pain and neurodegenerative disease management. According to Grand View Research, the global neuromodulation devices market was valued at $6.6 billion in 2022 and is projected to grow at a compound annual growth rate of 9.6% from 2023 to 2030 [Grand View Research, 2023]. The chronic pain management market is estimated at $83.5 billion in 2022, with forecasts reaching $145.2 billion by 2032 [Precedence Research, 2023].

Metric	Value
Global Neuromodulation Devices (2022)	$6.6B
Chronic Pain Management (2022)	$83.5B

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to the company's technology. Demand drivers are corroborated by public health reporting and the company's own grant citations.

Competition and Substitutes

Highland Instruments operates in a specialized niche of noninvasive neuromodulation. Its primary competitive surface is defined by its specific modality, electrosonic stimulation (ESStim), which it positions as a novel combination of electromagnetic and ultrasonic fields [Highland Instruments website].

• Incumbent medical device players: Large firms like Medtronic and Abbott Laboratories offer invasive neuromodulation solutions. Highland's noninvasive approach targets patients seeking to avoid surgical risks.
• Noninvasive stimulation challengers: Startups like Magnus Medical and Flow Neuroscience are advancing FDA-cleared, noninvasive neuromodulation devices. Highland's differentiation is its dual-modality technology and focus on chronic pain and Parkinson's disease.
• Pharmaceutical substitutes: For conditions like chronic osteoarthritis pain or Parkinson's disease, the dominant competitive set remains drug therapies. The value proposition for ESStim is adjunctive or alternative therapy.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated technology and market; no direct competitor names were captured in sources. Clinical trial and grant details are confirmed by press releases.

Opportunity

The headline opportunity is the creation of a category-defining, non-invasive therapeutic platform for chronic neurological disorders. The company's core ESStim technology has demonstrated statistically significant benefits across multiple, distinct clinical indications in randomized, controlled trials [PRNewswire, Aug 2022] [PRNewswire] [Physical Therapy Products].

Scenario	What happens	Catalyst	Why it's plausible
Pain Management First	ESStim becomes a standard-of-care adjunct therapy for chronic osteoarthritis pain.	FDA 510(k) clearance for the knee pain indication.	Positive outcomes in a Phase II trial with a Harvard Medical School affiliate.
Neurodegenerative Disease Platform	The company establishes ESStim as a foundational digital therapeutic for Parkinson's disease.	Successful completion of the ongoing NIH-funded Phase II RCT for postural instability.	Preliminary Phase I data showed improvements in UPDRS and gait metrics.

Data Accuracy: YELLOW -- Clinical trial claims are well-documented via press releases from research hospitals and NIH announcements. Market size comparables and specific growth catalysts are inferred from the company's published research focus and industry analogs.

Links

• Website: https://www.highlandinstruments.us
• LinkedIn: https://www.linkedin.com/company/highland-instruments

Sources

1. [PRNewswire, Aug 2022] Highland Instruments, Inc. has been Awarded Additional NIH Funding | https://www.prnewswire.com/news-releases/highland-instruments-inc-has-been-awarded-additional-nih-funding-for-their-opioid-use-disorder-studies-301671090.html
2. [Physical Therapy Products] New Clinical Trial to Investigate Postural Instability Technology | https://ptproductsonline.com/industry-news/research-development/new-clinical-trial-to-investigate-postural-instability-technology/
3. [Highland Instruments website] Highland Instruments | https://www.highlandinstruments.us
4. [ZoomInfo] Highland Instruments - Overview, News & Similar companies | https://www.zoominfo.com/c/highland-instruments-inc/374067164
5. [CBInsights] Highland Instruments - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/highland-instruments
6. [BioSpace] Highland Instruments, Inc. Announces Presentation of "Electrosonic Stimulation As Adjunctive Therapy To Dopaminergic Treatments In Parkinson's Disease" | https://www.biospace.com/highland-instruments-inc-announces-presentation-of-electrosonic-stimulation-as-adjunctive-therapy-to-dopaminergic-treatments-in-parkinson-s-diseas
7. [Business Wire, Oct 2012] Highland Instruments, Inc., Announces Presentation of “Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee” | https://www.prweb.com/releases/highland_instruments_inc_announces_presentation_of_effects_of_electrosonic_stimulation_on_the_perception_of_chronic_pain_due_to_osteoarthritis_of_the_knee_/prweb11341488.htm
8. [PRNewswire] Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., Jointly Announce Release of ALGEA 2 Clinical Trial Results Investigating Highland's Electrosonic Stimulation ("ESStim™") Technology to Treat Chronic Osteoarthritis Knee Pain | https://www.prnewswire.com/news-releases/spaulding-rehabilitation-hospital-at-harvard-medical-school-and-highland-instruments-inc-jointly-announce-release-of-algea-2-clinical-trial-results-investigating-highlands-electrosonic-stimulation-esstim-technology-to-tre-301417944.html
9. [Explorium.ai] Highland Instruments | https://www.explorium.ai/manufacturing/companies/highland-instruments
10. [RocketReach] Highland Instruments Information | https://rocketreach.co/highland-instruments-profile_b44401d5faaa240f
11. [Crunchbase] Highland Instruments - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/highland-instruments
12. [Grand View Research, 2023] Neuromodulation Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/neuromodulation-devices-market
13. [Precedence Research, 2023] Chronic Pain Management Market Size, Growth, Report 2023-2032 | https://www.precedenceresearch.com/chronic-pain-management-market